Comprehensive Evaluation of Rebif�k Based on Guideline for Comprehensive Evaluation of Medicine in China
XU Xiao-wei1, LIU Rong-ji1, MEI Dan1, CUI Li-ying2
1. Department of Pharmacy,Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730,China; 2.Department of Neurology,Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730,China
Abstract��OBJECTIVE Based on Guideline for Comprehensive Evaluation of Medicine in China, to make a comprehensive evaluation of Recombinant Human Interferon beta 1a,Rebif�k. METHODS Induction, summary and analyses were used, mainly according to National Pharmacopeias, diagnosis and treatment guidelines, drug instruction, clinical study literatures and official data related with Rebif, based on the nine sections of the Guideline including safety, efficiency, compliance, pharmacoeconomics and so on. RESULTS AND CONCLUSION The evaluation of Rebif is objective and comprehensive. The Guideline for Comprehensive Evaluation of Medicine in China is a relatively complete pharmaceutical review system.
��Сޱ,���ݼ�,÷��,����Ӣ. ���ݡ��й�ҩƷ�ۺ�����ָ�ϲο���١������Ƚ����ۺ�������[J]. �й�ҩѧ��־, 2015, 50(12): 1070-1074.
XU Xiao-wei, LIU Rong-ji, MEI Dan, CUI Li-ying. Comprehensive Evaluation of Rebif�k Based on Guideline for Comprehensive Evaluation of Medicine in China. Chinese Pharmaceutical Journal, 2015, 50(12): 1070-1074.
Group of Guideline for Comprehensive Evaluation of Medicine in China. Guideline for comprehensive evaluation of medicine in China .Drug Evaluation(ҩƷ����),2011, 8(18):6-22.
[2]
Instruction for Recombinant Human Interferon Beta 1a solution for Injection, Rebif�k. 2011.
[3]
Product Monograph for Recombinant Human Interferon Beta 1a, Rebif�k. 2011.
[4]
The University of British Columbia MS/MRI Analysis Group.PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology, 2001, 56(12): 1628-1636.
[5]
ROSSI C P, HANAUER S B, TOMASEVIC R, et al.Interferon beta-1a for the maintenance of remission in patients with Crohn��s disease: Results of a phase II dose-finding study. BMC Gastroenterol, 2009,9(3): 22.
[6]
ANDERSEN O, ELOVAARA I, HANSEN H J, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry, 2004,75(5): 706-710.
QIU W, HU X Q, PENG F H, et al. Clinical analysis of 19 cases of multiple sclerosis treated with interferon��-1a. Chin J Neurol(�л�����־),2008,41(2): 91-92.
[9]
CATHY H, REILLY. Drug Facts and Comparisons. 65th ed. St. Louis:Wolters Kluwer Health, 2011:2801-2804. PANITCH H, GOODIN D S, FRANCIS G,et al.Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology, 2002, 59(10): 1496-1506. FDA.FDA Patient Safety News:New Cautions on Beta Interferons for MS.Silver Spring,MD,2003 .http://www.fda.gov/downloads/Safety/FDAPatientSafetyNews/UCM417781.pdf�� WANG L D, JIANG Z J. Clinical Diagnosis and Management Guidelines(Neurology) . 1th ed. Beijing:People��s Medical Publishing House, 2008:123-133. Association of British Neurologists.Revised (2009) Association of British Neurologists��guidelines for prescribing in multiple sclerosis .London,WC,2009.Http://www.abn.org.uk." NICE.Multiple sclerosis: Management of multiple sclerosis in primary and secondary care .London, 2003. Http://www.guidance.nice.org.uk/cg8. GOODINDS, FROHMAN E M, GARMANY G P, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the AmericanAcademy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology, 2002,58(5):169-178. ZHANG X H, ZHAO Z G. Australia: Therapeutic Guidelines: Neurology(�Ĵ���������ָ��:���ֲ�). 2th ed. Beijing: Chemical Industry Press, 2006:125. Neuroimmunology Group of Neurology branch of Chinese Medical Association and the neural-immune branch of Chinese society of immunology. Expert consensus of diagnosis and treatment of multiple sclerosis in China . Chin J Neurol(�л�����־),2010,43(7): 516-521. FREEDMAN M S, BLUMHARDT L D, BROCHET B, et al.Interna-tional consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler, 2002,8(1): 19-23. MS-Therapie Konsensus Gruppe(MSTKG). Immunmodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt,1999,70(4): 371-386. Multipe Sklerose-Therapie-Konsensus Gruppe.Escalating immunomodulatory therapy of multiple sclerosis. Nervenarzt, 2001,72(2): 150-157. TILBERYCP,MOREIRAMA, MENDES M F, et al.Recommendations for the use of immunomodulatory drugs in multiple sclerosis: The BCTRIMS consensus. Arq Neuropsiquiatr, 2000,58(3A): 769-776. RICHARD N, JEREM Y C.Clinical Evidence(�ٴ�֤��(������,���İ�)). Beijing: Peking University Medical Press,2008: 592-596. EBERS, RICE G, LESAUX G, et al.Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet, 1998, 352(9139): 1498-1504. The Once Weekly Interferon for MS Study Group.Evidence of interferon beta-1a dose response in relapsing-remitting MS: The OWIMS study. Neurology, 1999,53(4): 679-686. ETEMADIFA R M, JANGHORBANI M, SHAYGANNEJAD V, et al.Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand, 2006, 113(5): 283-287. MURDOCH D, LYSENG-WILLIAMSON K A.Subcutaneous recombinant interferon-beta-1a(Rebif): A review of its use in relapsing-remitting multiple sclerosis. Drugs, 2005, 65(9): 1295-1312. MUNAFO A, TRINCHARD-LUGAN I, NGUYEN T X Q, et al. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol, 1998, 5(2): 187-193. LI W. Inspection Report for Pharmaceutical Imports: China, 2011JSZ 0280 . 2011-06-23. BP (2012)Vol ��. 2012:1147-1148. EP (2008)Vol ��. 2008:2255-2257. Ch. P(2010) Vol ��(�й�ҩ��2010���, ����). 2010:87, 439, 1208, 1254. USP (2011)Vol ��. 2011:1713, 1893, 3765, 3851, 4644. FDA.Enforcement Report for February 22,2012. Silver Spring,MD,2012.Http:www.fda.gov/Safety/recalls/enforcementreports/ucm293085.htm. LEPEN C, COYLE P, VOLLMER T,et al.Long-term cost effectiveness of interferon-beta-1a in the treatment of relapsing-remitting multiple sclerosis : An econometric model.Clin Drug Investig, 2003,23(9): 571-581. MEYERC M, PHIPPS R, COOPER D, et al.Pharmacy benefit forecast for a new interferon Beta-1a for the treatment of multiple sclerosis: Development of a first-line decision tool for pharmacy-budget planning using administrative claims data. J Manag Care Pharm,2003,9:168-174. GUO S, BOZKAYA D, WARD A, et al.Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: Modelling the clinical and economic implications. Pharmacoeconomics, 2009,27(1):39-53. NUIJTEN M, MITTENDORF T.A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. Clin Ther, 2010,32(4): 717-728. CHILCOT T J, MCCABE C, TAPPENDEN P, et al.Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ,2003,326(7388): 522-525. BELL C, GRAHAM J, EAMSHA W S,et al.Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: A markov model based on long-term clinical data. J Manag Care Pharm, 2007,13(3): 245-261. GLDBERGL D, EDWARDS N C, FINCHER C,et al.Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm, 2009,15(7): 543-555. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 1993,43(4): 655-661. ANTONETTI F, FINOCCHIARO O, MASCIA M.A comparison of the biologic activity of two recombinant IFN-�� preparations used in the treatment of relapsing-remitting multiple sclerosis. J Int Cytok Re,2002, 22(12): 1181-1184. SEAN C. Martindale . 36th ed. London: Pharmaceutical Press, 2009: 891-893. MICHAEL D. Physicians�� desk reference . 65th ed. Montvale: PDR network, 2011:1070-1074. SUN Z S. Drug evaluation heavy as Taishan.Drug Evaluation(ҩƷ����), 2010, 7(2):26-29. TAN Z X. XU P. Establishment of comprehensive drug evaluation system in China needs to be completed and further improvement.Drug Evaluation(ҩƷ����), 2011,8(18):4-5. WEI J X, ZHAO Z G. Discussion of method and application of drug evaluation .Drug Evaluation(ҩƷ����), 2010, 7(4):26-30. XU X W, HOU W J, JIN Y. Introduction of guideline for drug safety evaluation with an example.Drug Evaluation(ҩƷ����), 2010,7(2):30-38. LUO X, SHI L M, WANG R L. Evaluation of the clinical value of drugs .Drug Evaluation(ҩƷ����), 2010, 7(4):20-24.
2015, Vol. 50 
